Skip to main contentAI and Advanced
/
KILITCH · BSEMarket ticker unavailable · configure an authorised index feed
KI
BSE · Equity shares · Biotechnology & Drugs-3.95 · -2.19%
Kilitch Drugs India Ltd KILITCH
NSE:INR 176.25
BSE:INR 176.55
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Temporary source issue: live-price. Available sections remain usable while the affected layer retries on a later request.
AI analysis and Advanced tools for KILITCH
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 180.5
Day rangeINR 174.2 — INR 183.5
52-week rangeINR 121.1 — INR 226.5
Volume10,352
Market cap606.02
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)235.47
Net Income (INR Cr)30.17
EPS8.91
Research path: Interpret Kilitch Drugs India Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
KILITCHKilitch Drugs India Ltd1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 457.75 | 312.78 | 240.06 |
| Cash Equivalents | 15.77 | 2.87 | 10.58 |
| Other Liabilities Total | 0.68 | 0.25 | 0.17 |
| Long Term Debt | 58.6 | 27.77 | Not available |
| Common Stock Total | 34.96 | 16.08 | 16.08 |
| Other Current Assets Total | 21.73 | 0.12 | 0.19 |
| Total Assets | 457.75 | 312.78 | 240.06 |
| Total Equity | 279.65 | 202.33 | 176.29 |
| Long Term Investments | 22.89 | 22.86 | 22.85 |
| Retained Earnings(Accumulated Deficit) | 244.69 | 127.44 | 100.74 |
| Total Common Shares Outstanding | 3.5 | 3.29 | 3.29 |
| Tangible Book Valueper Share Common Eq | 74.85 | 55.81 | 47.6 |
| Goodwill Net | 17.69 | 18.54 | 19.38 |
| Total Liabilities | 178.1 | 110.45 | 63.77 |
| Total Debt | 88.71 | 49.42 | 31.65 |
| Short Term Investments | 53 | 49.57 | 50.11 |
| Cashand Short Term Investments | 68.77 | 59.31 | 69.02 |
| Total Receivables Net | 120.18 | 88.27 | 65.79 |
| Notes Payable/Short Term Debt | 30.11 | 21.65 | 31.65 |
| Accounts Receivable-Trade Net | 120.18 | 84.77 | 63.26 |
| Property/Plant/Equipment Total-Net | 188.72 | 92.82 | 48.12 |
| Minority Interest | -2.79 | -1.87 | -0.62 |
| Total Current Liabilities | 121.6 | 84.31 | 64.22 |
| Total Inventory | 11.52 | 26.02 | 10.91 |
| Accounts Payable | 79.65 | 54.16 | 25.59 |
| Other Currentliabilities Total | 11.85 | 8.5 | 6.98 |
| Total Long Term Debt | 58.6 | 27.77 | 0 |
| Intangibles Net | 0.26 | 0.35 | 0.44 |
| Other Long Term Assets Total | 4.58 | 2.88 | 2.56 |
| Note Receivable-Long Term | 1.41 | 1.42 | 0.72 |
| Total Current Assets | 222.2 | 173.92 | 145.99 |
| Accumulated Depreciation Total | Not available | -29.49 | -27.39 |
| Other Equity Total | Not available | 11.77 | 12.43 |
| Prepaid Expenses | Not available | 0.2 | 0.09 |
| Additional Paid-In Capital | Not available | 46.68 | 46.68 |
| Cash | Not available | 6.88 | 8.33 |
| Property/Plant/Equipment Total-Gross | Not available | 75.02 | 69.55 |
| ESOP Debt Guarantee | Not available | 0.35 | 0.35 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio2.57
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk55.28
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 63.77%
- FII
- 0.12%
- Other
- 36.11%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Kilitch Drugs (India) Ltd Technical Momentum Shifts Amid Mixed Indicator Signals - MarketsMojoMarket news · 20 Jul 2026, 8:00 am
Kilitch Drugs (India) Ltd Technical Momentum Shifts Amid Mixed Indicator Signals MarketsMojo
Price to earnings forward of Kilitch Drugs (India) Limited – BSE:KILITCH - TradingViewMarket news · 18 Jul 2026, 4:07 am
Price to earnings forward of Kilitch Drugs (India) Limited – BSE:KILITCH TradingView
Kilitch Drugs (India) Ltd Technical Momentum Shifts Signal Bullish Outlook - MarketsMojoMarket news · 18 Jul 2026, 2:00 am
Kilitch Drugs (India) Ltd Technical Momentum Shifts Signal Bullish Outlook MarketsMojo
Kilitch Drugs Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics - MarketsMojoMarket news · 2 Jul 2026, 8:11 am
Kilitch Drugs Valuation Shifts Signal Price Attractiveness Change Amid Sector Dynamics MarketsMojo
Kilitch Drugs (India) Ltd is Rated Hold by MarketsMOJO - MarketsMojoMarket news · 2 Jul 2026, 2:27 am
Kilitch Drugs (India) Ltd is Rated Hold by MarketsMOJO MarketsMojo
Kilitch Drugs (India) Ltd Shows Bullish Momentum Amid Technical Upgrades - MarketsMojoMarket news · 1 Jul 2026, 3:26 pm
Kilitch Drugs (India) Ltd Shows Bullish Momentum Amid Technical Upgrades MarketsMojo
Corporate actions
Events
- board MeetingsAudited Results
- bonusBonus issue of equity shares in the ratio of 1:1 of Rs. 10/-.
- annual General MeetingEGM
- board MeetingsQuarterly Results & Bonus issue
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- rightsRights issue of equity shares of Rs. 10/- in the ratio of 2:23 @ premium of Rs. 347/-.
Rusaka Markets Community
Discussion and sentiment for Kilitch Drugs India Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- KILITCH
- BSE Code
- 524500
Questions
Stock FAQ
What is the symbol and ISIN of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has the symbol KILITCH and ISIN - INE729D01010.
What is the current price of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd is currently trading at INR 176.55.
What are the year high and year low of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a year high of INR 226.50 and a year low of INR 121.10.
What is the market capitalization of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a market capitalization of INR 606.02 crore.
What is the P/E ratio of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a P/E ratio of NA.
What is the dividend yield of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a dividend yield of NA.
How is the financial performance of Kilitch Drugs India Ltd based on revenue, net income, and EPS?
Kilitch Drugs India Ltd has revenue of INR 235.47 crore, net income of INR 30.17 crore, and EPS of NA.
What is the book value of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a book value of NA.
What is the debt-to-equity ratio of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Kilitch Drugs India Ltd?
Kilitch Drugs India Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 2.57.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.